June 26-28, 2018

Frankfurt, Germany

Day One
Wednesday 27th June, 2018

Day Two
Thursday 28th June, 2018

09.00
Chair’s Opening Remarks

Avenues to Rational Combination Therapies to Advance Existing Standards of Care

09.10
Mechanisms of IMLYGIC, the Bedside to Bench Learning Loop

  • Jing Qing Global Discovery Research Lead for IMLYGIC, Amgen

Synopsis

  • Introduction to IMLYGIC and the summary of OPTiM Ph.III trial
  • MOA studies of IMLYGIC using preclinical models, as a single agent and in
    combination with checkpoint blockade
  • Early insights into clinical activities of IMLYGIC in combination with Ipilimumab and
    Pembrolizumab

09.40
Small Molecule Enhancers of Oncolytic Immunotherapy

  • Jean-Simon Diallo Assistant Professor, Biochemistry, Microbiology & Immunolog, University of Ottawa

Synopsis

  • Novel small molecules termed “viral sensitizers” work in a variety of ways to deter the
    immune response away from the virus, allowing for vastly improved infection
  • Here we will present recent data highlighting the capacity of vanadium-based
    compounds to shift type I antiviral responses towards a type II pro-inflammatory
    phenotype that favours adaptive anti-tumor effects
  • We will also present our recent findings regarding the effectiveness of targeting
    NF-κB nuclear translocation using both novel and approved drugs as in combination
    with oncolytic viruses in vitro and in vivo.

10.10
Overview of the Immunotherapy Combinations with HF10 from Clinical Trial and Basic Research

  • Hideki Kasuya Director & Professor, Cancer Immune Therapy Center, Nagoya University

Synopsis

  • Overview of clinical trial using HF10 in Japan and USA
  • New generation of HF10 with immune related therapeutic molecules
  • New strategy of oncolytic virus with CAR T-cell

10.40
Morning Refreshments

11.10
Panel Discussion: Explore Novel Approaches to Identify the Most Rational Combinations

  • Akseli Hemminki Founder, Chief Executive Officer & Chairman of the Board, TILT Biotherapeutics
  • John Bell Professor of Medicine, Ottawa Health Research Institute
  • Jing Qing Global Discovery Research Lead for IMLYGIC, Amgen
  • Kah Whye Peng CTO & Co-founder, Vyriad

Synopsis

  • What virus is best evolved to add a measurable contribution in a combination therapy
  • Methods to identify and quantify if the virus is importantly contributing to the outcome of therapy

Current Status for Systemic Delivery of Viral Therapy

11.40
VSV-GP Therapy is Effective Though Direct Tumor Lysis and Stimulation of an Anti-Tumor Immune Response

Synopsis

  • I.T. vs. I.V. in mouse tumor models
  • VSV-GP as potent OV for I.V. therapy
  • Benefits and handicaps of I.V. treatment of armed OVs

12.10
Systemic Cancer Therapy Using Oncolytic VSVs: The Voyager Platform

Synopsis

  • VSV is a low seroprevalence RNA virus with extensively studied oncolytic activity
  • Vyriad is developing this platform for systemic single cycle virotherapy, both as standalone
    therapy and in combination with other IO agents
  • Clinical and preclinical progress will be discussed

12.40
Lunch and Networking

13.40
Biological Therapies for Gliomas – Oncolytic Viruses and Bone Marrow Derived Mesenchymal Stem Cells

  • Frederick Lang Professor & Chair of Clinical Research, Department of Neurosurgery, MD Anderson

Synopsis

  • The delivery of oncolytic virotherapy has been a challenge with current methods
    depending on intratumoral delivery
  • Stem cells have been a potential solution to overcome this challenge
  • This talk will outline the use of bone marrow derived mesenchymal stem cells for the
    delivery of DNX2401

Efficacious Preclinical Models which show Best Human Translation

14.10
Panel Discussion : Animal Model Systems to Predict Human Translation

  • Patrik Erlmann Head of Research & Development, ViraTherapeutics
  • Daniel Katzman Chief Executive Officer, Unleash Immuno Oncolytics
  • Frederick Lang Professor & Chair of Clinical Research, Department of Neurosurgery, MD Anderson

Synopsis

  • Discuss the most appropriate model to ensure reliable data is collected to make preclinical conclusions
  • Explore past clinical data to acknowledge the quality of the preclinical models
  • Explore varying infections in different specie cell types and difficulty in assessing presentation
  • Determine and develop transgenic models to increase translation results

14.40
Biomarkers to Track and Measure Clinical Efficacy

Synopsis

  • Explore what biomarkers should be used to test efficacy in preclinical studies
  • Experience from GBM clinical trials

15.10
Chair’s Closing Remarks

15.10
End of Day 2